Welcome to our dedicated page for Cytomx Therapeutics news (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on Cytomx Therapeutics stock.
CytomX Therapeutics develops oncology biologics built on its PROBODY therapeutic platform, which masks and conditionally activates antibody-based therapies in the tumor microenvironment. News about CTMX commonly covers clinical updates for varsetatug masetecan, or Varseta-M, an EpCAM PROBODY ADC studied in advanced colorectal cancer and other EpCAM-expressing tumors, as well as CX-801, a masked Interferon-alpha-2b program initially developed in advanced melanoma.
Company updates also address financial results, research and development spending, cash runway, equity financings, and collaboration activity with Amgen, Regeneron, and Moderna. Recurring pipeline coverage includes dose-expansion data, combination-study activity, regulatory interactions, and PROBODY platform applications such as bispecific immunotherapies and T-cell engagers.
CytomX Therapeutics, Inc. (Nasdaq: CTMX) will release its Q2 2022 financial results on August 4, 2022, after U.S. market closure. A conference call will follow at 5:00 p.m. ET to discuss the results and provide corporate updates. Participants can join via the company’s webcast.
CytomX focuses on oncology therapeutics, leveraging its Probody® technology. The pipeline includes seven candidates, with three in Phase 2 studies for various cancer types.
CytomX Therapeutics (Nasdaq: CTMX) is restructuring to focus on its next-generation, conditionally activated therapeutics, including the IFN alpha-2b cytokine and EpCAM-directed ADC, with Investigational New Drug (IND) applications planned for 2023. The company will reduce its workforce by approximately 40% to extend its cash runway to 2025 while maintaining current partnerships with AbbVie and Bristol Myers Squibb. Ongoing clinical programs include CX-2029 and CX-904, with data updates anticipated in 2022. The leadership aims to leverage its Probody platform to enhance cancer therapies.
CytomX Therapeutics announced the completion of a Phase 2 study of praluzatamab ravtansine in patients with HR+/HER2-non-amplified breast cancer, achieving a primary endpoint of a confirmed objective response rate (ORR) of 15%. This study also reported a clinical benefit rate of 40% at 24 weeks and a median progression-free survival of 2.6 months. However, Arm B of the study, targeting triple-negative breast cancer, failed to meet its endpoint, leading to its discontinuation. The company plans to pursue partnerships for further development given current financial conditions.
CytomX Therapeutics, Inc. (Nasdaq: CTMX) granted stock options for 109,000 shares at $1.72 per share to two new employees on June 15, 2022. This grant is part of the Company’s 2019 Employment Inducement Incentive Plan, approved by its board of directors in August 2020. CytomX is advancing conditionally activated oncology therapeutics, including its investigational antibody-drug conjugates praluzatamab ravtansine and CX-2029, which are in Phase 2 studies targeting challenging cancer types.
CytomX Therapeutics (Nasdaq: CTMX) announced that CEO Sean McCarthy will present at the Jefferies Healthcare Conference on June 8, 2022, at 2:00 p.m. ET. A live webcast of the presentation will be available on CytomX’s website, with an archived replay accessible for 30 days.
CytomX is a clinical-stage biopharmaceutical company focused on conditionally activated cancer therapies. Its pipeline includes investigational drugs like praluzatamab ravtansine and CX-2029, targeting complex cancers. The company partners with leaders in oncology, including AbbVie and Bristol Myers Squibb.
CytomX Therapeutics (Nasdaq: CTMX) has announced the initiation of a Phase 1 dose-escalation study for its investigational bispecific antibody, CX-904, targeting EGFR and CD3 on T cells. This study marks the sixth candidate from CytomX's Probody platform to enter clinical trials, emphasizing its commitment to innovative cancer therapies. The trial aims to improve therapeutic windows in treating solid tumors, leveraging conditionally activated T-cell engagement. Early preclinical models indicate promising potential, and trial results may address unmet needs in multiple tumor types.
CytomX Therapeutics reported significant progress in its clinical studies and financial results for Q1 2022. Patient enrollment in Arm A of the Phase 2 study for praluzatamab ravtansine in breast cancer is complete, with initial data expected in H2 2022. The CX-2029 study's enrollment for squamous non-small cell lung cancer is also complete, with updates anticipated in the same period. The company has $263 million in cash, while revenue increased to $17.1 million. R&D expenses rose to $30.6 million, reflecting ongoing clinical developments.
CytomX Therapeutics, Inc. (Nasdaq: CTMX) will announce its first quarter 2022 financial results on May 5, 2022, after U.S. markets close. A conference call and webcast will follow at 5:00 p.m. ET to discuss the results and provide a corporate update. Interested parties can access the live webcast on the company’s Events and Presentations page. CytomX, a leader in conditionally activated oncology therapeutics, features a robust pipeline including investigational drugs for various cancer types.
CytomX Therapeutics (Nasdaq: CTMX) announced the impending retirement of John A. Scarlett, M.D. from its board, effective at the next annual stockholder meeting on June 15, 2022. Dr. Scarlett has been on the board since June 2016, contributing significantly to the company as chair of the Compensation Committee. CEO Sean McCarthy highlighted Dr. Scarlett's invaluable biopharma experience during his tenure. CytomX is focused on developing innovative oncology therapeutics, including investigational antibody-drug conjugates and immunotherapeutic candidates targeting difficult-to-treat cancers.
CytomX Therapeutics (CTMX) announced the retirement of Frederick W. Gluck from its board of directors, effective June 30, 2022. Gluck, a co-founder of the company, has been influential since its inception in 2008. His strategic insight has been key in positioning CytomX as a leader in oncology therapeutics. The board will remain robust with eight directors post-retirement, seven of whom are independent under NASDAQ rules. CytomX is recognized for its unique Probody technology, focusing on conditionally activated biologics aimed at improving cancer treatment outcomes.